Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Phase 3 Unknown 244 enrolled Peking University

RandomizedParallel-groupOpen-labelTreatment

Primary objective of the study is to compare the efficacy and safety of CDOP versus CHOP for newly diagnosed peripheral T-cell lymphoma (PTCL).

Evaluation	Drug	Modality	Dose	Route
Comparator	Doxorubicin	Other / unclassified	50 mg/m2	Intravenous
Subject	Pegylated liposomal doxorubicin	Unknown	40 mg/m2	Intravenous
Background	Cyclophosphamide	Other / unclassified	750 mg/m2	Intravenous
Background	Prednisone	Other / unclassified	100 mg/m2	Oral
Background	Vincristine	Small molecule	1.4 mg/m2	Intravenous